Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of sacubitrilâ€“valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels

Yan Duan¹ , Meimei Yu², Yan Xu³

¹College of Pharmacy, Ningxia Medical University, Yinchuan, China; ²Department of Emergency, Binhu Hospital of Hefei City, China; ³Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230061, China.

For correspondence:- Yan Duan Email: yanduan1329@163.com Tel:+8613195069696

Accepted: 28 May 2023 Published: 30 June 2023

Citation: Duan Y, Yu M, Xu Y. Effect of sacubitrilâ€“valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels. Trop J Pharm Res 2023; 22(6):1335-1340 doi: 10.4314/tjpr.v22i6.25

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To assess the effect of sacubitril–valsartan on chronic heart failure (CHF).

Methods: A total of sixty CHF patients were divided randomly into two groups of thirty patients each (conventional and sacubitril-valsartan groups, respectively). Conventional anti-heart-failure treatment was used in the conventional group, while the sacubitril–valsartan group received sacubitril–valsartan (25 mg) taken orally, twice daily, followed by up-titration to 100 mg, twice daily. After 3 months of treatment, the six-minute walking test (6-MWT), left ventricular ejection fraction (LVEF) scores, left ventricular end-diastolic diameters, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and NT-proBNP/brain natriuretic peptide (BNP) levels, treatment efficacy, and adverse cardiovascular events were evaluated.

Results: After three months of treatment, the level of serum NT-proBNP and NT-proBNP/BNP in the sacubitril–valsartan group was lower, while the levels of LVEF and 6-MWT were higher (p < 0.05), compared with the conventional group. Sacubitril-valsartan treatment had a better therapeutic effect than the conventional treatment, while readmission rate for heart failure was lower in the sacubitril-valsartan treatment group (p < 0.05). Both LVEF and 6-MWT values had significantly negative correlation with NT-proBNP/BNP ratio.

Conclusions: The efficacy of sacubitril-valsartan in the treatment of CHF is significant and improves the short-term prognosis of patients. These findings will require validation in large multicentre trials and over a longer duration of study.

Keywords: Chronic heart failure, Sacubitrilâ€“valsartan, NT-proBNP/BNP ratio, Cardiac function